Valuation: Endonovo Therapeutics, Inc.

Market Cap 2.77M 2.42M 2.24M 2.06M 3.9M 267M 3.96M 26.7M 10.48M 130M 10.41M 10.19M 450M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.68M 8.01M 7.36M 13.94M 955M 14.18M 95.58M 37.5M 467M 37.28M 36.46M 1.61B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 29/02/2012
Investor Relations Contact - 30/04/2014
Corporate Officer/Principal 70 28/02/2022
Director TitleAgeSince
Chairman 61 29/02/2012
Change 5-day change 1-year change 3-year change Capi.($)
-9.62%-18.42% - - 181K
+3.13%+13.95%+64.21%+94.35% 57.82B
+0.16%-5.70%+54.61%+71.71% 53.71B
-1.91%-9.32%+2.53%+418.07% 23.8B
+0.29%-1.25%-18.37%-14.36% 23.26B
-0.56%+6.10%+44.56%-3.75% 20.7B
-1.32%-3.65%+32.21%-30.77% 17.81B
+10.00%-4.30%+208.33%+370.99% 16.9B
-2.61%+10.00%+47.02%+699.54% 16.36B
+1.61%-1.40%+25.64%+193.38% 13.96B
Average -0.11%+1.42%+51.19%+199.91% 27.15B
Weighted average by Cap. +1.06%+1.35%+50.84%+158.44%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 7.03 0.1 0.7 0.28 3.44 0.27 0.27 11.85 0.14 0.12 0.11 0.1 0.19 13.02 0.19 1.3 0.51 6.37 0.51 0.5 21.94
Net income -3.1M -2.71M -2.5M -2.3M -4.36M -299M -4.44M -29.9M -11.73M -146M -11.66M -11.4M -503M -18.47M -16.15M -14.9M -13.7M -25.95M -1.78B -26.4M -178M -69.8M -869M -69.38M -67.86M -2.99B
Net Debt 7.1M 6.2M 5.72M 5.26M 9.97M 683M 10.14M 68.32M 26.81M 334M 26.65M 26.06M 1.15B 7.15M 6.25M 5.77M 5.3M 10.05M 688M 10.22M 68.88M 27.02M 336M 26.86M 26.27M 1.16B
Logo Endonovo Therapeutics, Inc.
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-